Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 7, 2026
Reporting period
Not applicable
Filed with the SEC
May 9, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001225208-26-005045
Filed / recorded
May 9, 2026, 1:16 AM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Edwards Lifesciences Corp
Issuer CIK
1099800
Ticker
EW
Reporting person
Daniel J. Lippis
Relationship
Officer
Officer title
CVP, TAVR
Security
Performance Rights
Table
Derivative (Table II)
Transaction date
May 7, 2026
Transaction code
A
Shares / units
7,850
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
7,850
Ownership form
Direct
Amendment
No
Footnotes from the filing
Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.